BLOMIA TROPICALIS EXTRACT for Allergy to Blomia tropicalis

Inclusion criteria

• {"criterion_text":"- Female or male aged 18 to 64 years, both included."}
• {"criterion_text":"- Subjects who have signed and dated the informed consent form."}
• {"criterion_text":"- Subjects must reside in a geographical area where allergic problems caused by Blomia tropicalis are relevant."}
• {"criterion_text":"- Positive medical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to Blomia tropicalis"}
• {"criterion_text":"- A positive prick-test (mean wheal diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE against complete extract or any molecular component to the allergenic source."}
• {"criterion_text":"- The area of the wheal obtained with 10 mg/mL histamine dihydrochloride should be ≥ 7 mm², which corresponds to a mean wheal diameter ≥ 3 mm."}
• {"criterion_text":"- The area of the wheal obtained with negative control should be < 7 mm², which corresponds to a mean wheal diameter < 3 mm."}
• {"criterion_text":"- Women of childbearing age (i.e following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilization methods, such as hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must present a negative urine pregnancy test at the time of enrollment in the trial, as well as a confirmed menstrual period."}
• {"criterion_text":"- Women of childbearing age must commit to using a highly effective and adequate contraception method during the trial and up to 72 hours after the end of treatment with the investigational medicinal product. Such methods include combined (estrogen and progestogen containing) hormonal; contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence."}

Exclusion criteria

• {"criterion_text":"- Subjects outside the age range."}
• {"criterion_text":"- Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc.)."}
• {"criterion_text":"- States in which the subject is unable to offer cooperation and severe psychiatric disorders."}
• {"criterion_text":"- Pregnant or potentially pregnant women and breastfeeding women."}
• {"criterion_text":"- Subjects with known phenol allergy."}
• {"criterion_text":"- Subjects who have previously received immunotherapy within the last 5 years for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Blomia tropicalis extract."}
• {"criterion_text":"- Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in whom discontinuation of systemic antihistamine treatment is contraindicated."}
• {"criterion_text":"- Subjects who have previously exhibited a severe adverse reaction during diagnostic skin prick tests."}
• {"criterion_text":"- Subjects on treatment with ß-blockers."}
• {"criterion_text":"- Use of drugs that could interfere with skin prick test reactions (e.g., antihistamines)."}
• {"criterion_text":"- Clinically unstable subjects (acute asthma, febrile, etc.)."}
• {"criterion_text":"- Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives)."}
• {"criterion_text":"- Subjects with active herpes simplex viral infection, or herpes varicella zoster in the area where the prick test is performed."}

Primary endpoints

• {"endpoint_text":"- The primary efficacy endpoint involves measuring the area (mm2) of the induced wheal on the skin upon applying each of the 3 concentrations of the allergenic extract, as well as those induced by positive (histamine) and negative controls, through the prick test.","definition_or_measurement_approach":"Measure the area (mm2) of the induced wheal on the skin for each of the 3 concentrations of Blomia tropicalis extract and for positive (10 mg/mL histamine dihydrochloride) and negative controls using the prick test."}

Secondary endpoints

• {"endpoint_text":"- Overall rate, seriousness, and ratio of any adverse event (AE) by administration and by subject.","definition_or_measurement_approach":"Collection and classification of adverse events by administration and by subject, with assessment of rate, seriousness, and proportion."}
• {"endpoint_text":"- Assessment of administration site reactions, systemic reactions and any medication administered for the treatment of adverse reaction (AR).","definition_or_measurement_approach":"Assessment and recording of local administration site reactions, systemic reactions, and medications given to treat adverse reactions."}

Spain

Earliest CTIS Part Ii Submission Date

07-08-2025

Latest Decision Or Authorization Date

20-10-2025

Processing Time Days

74

Number Of Sites

1

Number Of Participants

30

Primary sponsor

Full Name

Inmunotek S.L.

Organisation Type

Pharmaceutical company

Country Of Registered Address

Spain